Solutions For Advanced AI Models
Foundation AI models in biology and medicine need vast, structured, high-quality datasets - just like LLMs do. No equivalent of GPT-level training sets exist (yet) in cellular biology.
However, available biological data is heterogeneous, noisy, and sparse, especially for perturbation-based cell models.
CellCodex's mission is to generate, curate and analyze the highest-quality cell perturbation data for partners through our fully tailored experiment to insight platform. Our aim is to empower advanced AI models with scalable and reproducible training data.
OUR SOLUTIONS
Cell Engineering and Scale Up
We create customized human cell models with scalable production, enabling more predictive drug discovery and AI-driven biology. Through precision cell engineering, we deliver consistent, reproducible results across diverse therapeutic areas.
Genetic Screens for Target Discovery
We perform CRISPR and other perturbation screens in human complex models designed to uncover novel drug targets and reveal disease mechanisms. Our comprehensive screening platforms provide clients with actionable insights for target.
Genetic Screens at Scale for AI
We deliver large-scale CRISPR and other perturbation datasets in human cells that are clean, well-annotated, and AI-ready. These datasets power next-generation AI models for drug discovery and therapeutic development.
Figure: AI-driven cellular modelling pipeline
CellCodex combines various perturbation components, including genetic data, high-throughput CRISPR edits, iPSC-derived cell types, complex in vitro models, environmental exposures, and single-cell readouts/imaging to create multimodal data sets that are suitable for training advanced AI models.
OUR TEAM
Emmanouil Metzakopian
Dr Emmanouil Metzakopian is the co-founder and Chief Executive Officer at CellCodex. He is the former Chief Scientific Officer at bit.bio , a cell coding company, where he led the Transcription Factor discovery, cell type development and cell therapy innovation platform using the latest cutting-edge genetic screening and cell programming technologies. Emmanouil received his Ph.D. in midbrain development from University College London and the National Institute for Medical Research (now part of the CRICK institute). He then moved to the Sanger Institute in Cambridge, UK, focusing on gene editing and genetic screening for therapeutic target identification while developing his research group. During this time, Emmanouil identified novel reprogramming factors and produced the Sanger CRISPR arrayed libraries distributed worldwide by MERCK. Finally, Emmanouil moved his lab to the UK Dementia Research Institute at the University of Cambridge, where he specialised in iPSC-derived neurodegenerative disease models and CRISPR-Cas9 genetic screens for therapeutic targets, where he identified disease-modifying genetic targets in neurodegenerative human models.
Grant Belgard
Dr Grant Belgard is the co-founder and Chief Technology Officer at CellCodex. In this capacity, he leads the technical vision and builds the platform that prepares large‑scale gene‑perturbation data for training virtual cell models. A computational biologist and product‑minded engineering leader, he brings experience from founding The Bioinformatics CRO, a distributed bioinformatics services firm, and from building out the bioinformatics function at bit.bio, bridging experimental design with cloud‑native data engineering and machine learning for single‑cell and perturbational datasets. He earned his doctorate at the University of Oxford as a Marshall Scholar with joint training at the NIH (NHGRI), completed a postdoctoral fellowship at UCLA, an Executive MBA from Quantic, and earlier quadruple‑majored at Rice University. Grant’s focus on rigorous measurement and quality control for modelling cellular responses enables CellCodex to accelerate discovery with confidence.
Tom Weaver
Dr. Tom Weaver is a co-founder and Chairman at CellCodex. A seasoned scientist and angel investor specialising in genetics, genomics, and drug discovery, he earned his PhD in Oncology from the University of Wisconsin–Madison Medical School and completed post-doctoral training in genetics at the MRC Laboratory of Molecular Biology and the University of Cambridge. Dr Weaver's career includes serving as an MRC Director in Oxford, where he managed the UK’s largest infrastructure for generating mouse models of human disease.
Leveraging his deep scientific insight and extensive entrepreneurial experience, Dr Weaver translates breakthrough science into impactful therapeutic and diagnostic innovations. He has a proven track record of creating and scaling life science ventures from inception to exit. His expertise lies in building business and technology strategies, directing high-performing teams, and managing complex partnerships across academia, biotech, and pharma. His entrepreneurial portfolio includes Hexagen, Geneservice, Congenica, NextGen Diagnostics, PetMedix, Maxion, ArkVax, and Elijo Biotherapeutics.
Ravi Moorthy
Ravi Moorthy is a co-founder and Chief Communications Officer at CellCodex. In this capacity, he leverages his extensive experience working with organisations of various sizes in positioning themselves in the market and rapidly scaling their operations. His focus will be on business development, communications and marketing.
Prior to CellCodex, Ravi was Vice President of Communications at Scorpion Therapeutics, a precision oncology biotech start-up that was acquired by Eli Lilly based on the merits of its lead program, a PI3K⍺ inhibitor. He has worked across multiple parts of the healthcare systems, including biopharma, health systems and health IT.
Andreas Andreou
Dr. Andreas Andreou is head of Functional Genomics at Cellcodex. He is also Co-founder and Chief Scientific Officer at Prozymi Biolabs. He possesses deep expertise in synthetic biology, DNA assembly technologies, functional genomics, and cellular engineering across multiple organisms (iPSCs, yeast, plants, bacteria) with proven commercialisation success and patentable innovations. He received his PhD in Synthetic Biology from the University of Edinburgh.
Eve Coomber
Eve Coomber is the Head of Stem Cell Biology at CellCodex. In this capacity, she partners with clients to design scalable solutions and deliver high-quality cell perturbation data. With over 13 years of experience in genetic engineering, functional genomics, and stem cell biology, Eve has a proven track record of designing large-scale screening strategies and building innovative platforms that deliver reproducible, high-impact data.
For a decade, Eve worked at the Wellcome Sanger Institute, specialising in genetic engineering and developing new models, tools, and screening techniques. She led the development of a high-throughput single-cell RNA-Seq pipeline for UK Biobank. In her move to biotech, she drove a novel large-scale screening program that accelerated stem cell-derived product discovery and was instrumental in filing disruptive Intellectual Property. Eve’s work is defined by her passion for innovation, scientific rigour, and operational excellence, and she is a strong advocate for collaborative research.
OUR ADVISORS
Stathis Megas
AI/ML Advisor
Dr Stathis Megas is currently an Accelerate Science Fellow funded by Schmidt Sciences at the University of Cambridge, and an incoming fast-track tenure Assistant Professor at the Department of Medicine III and the Centre for AI in Medicine at the Medical University of Vienna.
Stathis is a machine learning scientist using mathematics to design novel neural network architectures tailored to life science tasks, with the goal of driving discoveries in biomedicine. His research has focused on engineering cell fate and establishing the new field of perturbation models of virtual tissues.
Arthur L. Gilly
Bioinformatics & Statistical Genetics Advisor
Dr Arthur Gilly is a bioinformatician and statistical geneticist with over a decade of experience analysing large-scale omics datasets and leading interdisciplinary teams across academia, industry, and startups. Arthur has contributed to landmark projects in human genomics and developed widely used tools for translational data analysis and genomic data infrastructure. Currently Senior Manager in Translational Genetics at Regeneron Genetics Centre, his work bridges statistical genetics, machine learning, and software engineering to advance data-driven discovery. Arthur is also co-founder of AdaptAI, a startup applying AI to remote sensing, and Makerbox Lao, a nonprofit makerspace fostering STEM innovation.
NEWS AND UPDATES
Listen to co-founder and CEO, Manos Metzakopian, and Grant Belgard, our co-founder and the CTO, discuss CellCodex's mission to provide high-quality, scalable cellular perturbation data, ready to train advanced AI models for biology.
Our co-founder and CEO sat down with the Cambridge Independent to discuss CellCodex's vision to bridge the worlds of biology and AI. Read the interview at the link below.
ADDRESS
CellCodex Technology Limited
Meditrina Building
Babraham Research Campus
Cambridge, United Kingdom
CB22 3AT
© 2025 CellCodex Technology Limited. All rights reserved.